Switch to:

Ratios

vs
industry
vs
history
P/E(ttm) 20.74
PBE's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 20.74 )
Ranked among companies with meaningful P/E(ttm) only.
PBE' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.98
Current: 20.74
0
23.98
PE(NRI) 20.74
PBE's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 20.74 )
Ranked among companies with meaningful PE(NRI) only.
PBE' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.98
Current: 20.74
0
23.98
P/B 4.93
PBE's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 4.93 )
Ranked among companies with meaningful P/B only.
PBE' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.35
Current: 4.93
0
5.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.69
PBE's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 0.69 )
Ranked among companies with meaningful Dividend Yield only.
PBE' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 0.69
0
1.87
Yield on cost (5-Year) 0.69
PBE's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 0.69 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PBE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.87
Current: 0.69
0
1.87

More Statistics

Short Percentage of Float0.00%
52-Week Range $34.50 - 44.35
Shares Outstanding (Mil)5,600,000.00
» More Articles for PBE

Headlines

Articles On GuruFocus.com
Third Avenue Management's Top 5 Stock Buys of Q4 Feb 21 2017 
Re-Questioning the Death of Buy & Hold Investing Feb 21 2017 
Baron Opportunity Fund Comments on CoStar Group Feb 21 2017 
Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical Feb 21 2017 
Baron Opportunity Fund Comments on Splunk Feb 21 2017 
Baron Opportunity Fund Comments on Edwards Feb 21 2017 
Baron Opportunity Fund Comments on Intuitive Surgical Feb 21 2017 
Baron Opportunity Fund Comments on Illumina Feb 21 2017 
Baron Opportunity Fund Comments on CoStar Group Feb 21 2017 
Baron Opportunity Fund Comments on Amazon.com Feb 21 2017 

More From Other Websites
What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
Trump Attacks Biotech & Pharma: ETFs Bleed Jan 12 2017
What’s in Incyte’s Product Portfolio? Jan 09 2017
POWERSHARES EXCHANGE TRADED FUND TRUST Financials Dec 15 2016
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
Biotech ETFs Slumping on Q3 Results Nov 08 2016
4 Frightful ETFs of This Year Oct 27 2016
Is the Dividend ETF Bull Run Over? Oct 07 2016
3 ETFs to Buy for a Media Merger Frenzy Oct 05 2016
How Are Eli Lilly’s Business Segments Performing? Sep 01 2016
Why Did Hormel Foods Increase Its Fiscal 2016 Guidance? Aug 24 2016
The Zacks Analyst Blog Highlights: PureFunds ISE Junior Silver ETF, SPDR S&P Technology Hardware... Aug 23 2016
Top Tech ETFs Of 2016 Aug 04 2016
This Seasonal ETF Is Ripe For The Pickin' This Summer Jul 27 2016
A Consumer Staples ETF To Feast On Jul 25 2016
Restaurants Reflect Consumption Trends (Literally) Jul 23 2016
Why Are So Many Analysts Rating B&G Foods a ‘Hold’? Jul 12 2016
Why Did Cal-Maine Shares Fall 23% in the Last 3 Months? Jun 29 2016
What Lies Ahead for Biotech ETFs? May 13 2016
Hain Celestial Traded above Key Moving Averages May 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK